To help ensure patient safety, a Coram clinician may notify a patient and/or their physician of these labeling updates when appropriate.
ABRILADA (DALIMUMAB-AFZB) The Warnings and Precautions section of the Package Insert was updated to include Uveitis (UV) under malignancies in adults. The Clinical Trials Experience section was updated to detail infections, tuberculosis and opportunistic infections, liver enzyme elevations and other adverse reactions relating to UV.
Reference: Drug Safety-related Labeling Changes (SrLC) (fda.gov)
This article contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Coram.